PE20090957A1 - Moduladores de gamma secretasa - Google Patents

Moduladores de gamma secretasa

Info

Publication number
PE20090957A1
PE20090957A1 PE2008001303A PE2008001303A PE20090957A1 PE 20090957 A1 PE20090957 A1 PE 20090957A1 PE 2008001303 A PE2008001303 A PE 2008001303A PE 2008001303 A PE2008001303 A PE 2008001303A PE 20090957 A1 PE20090957 A1 PE 20090957A1
Authority
PE
Peru
Prior art keywords
diseases
secretasa
cycloalkyl
modulators
gamma modulators
Prior art date
Application number
PE2008001303A
Other languages
English (en)
Inventor
Zhaoning Zhu
Brian A Mckittrick
William J Greenlee
Robert D Mazzola
John P Caldwell
Xianhai Huang
Chad E Bennett
Hubert B Josien
Duane A Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090957(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090957A1 publication Critical patent/PE20090957A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE W ES -S(O)-, -S(O)2- O -C(O)-; U ES UN ENLACE, -C(O)-, -O-, N(R5), C(R3)(R4); X ES -N(R14)- O -C(R6)(R7)-; LAS LINEAS DISCONTINUAS (---) REPRESENTAN ENLACES OPCIONALES; R1, R2, R3, R4, R5, R6, R7, R8, R9 Y R14 SON ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R10 ES CICLOALQUILO, CICLOALQUILAQUIL, HETEROARILO, ENTRE OTROS; R12 ES ARILO, HETEROARILALQUILO, -CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: A9, A10, A11, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE GAMMA SECRETASA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL TALES COMO ENFERMEDADES NEURODEGENERATIVAS, ENFERMEDADES RELACIONADAS CON LA DEPOSICION DE PROTEINA AMILOIDE
PE2008001303A 2007-08-06 2008-08-04 Moduladores de gamma secretasa PE20090957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95417807P 2007-08-06 2007-08-06

Publications (1)

Publication Number Publication Date
PE20090957A1 true PE20090957A1 (es) 2009-07-13

Family

ID=40032527

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001303A PE20090957A1 (es) 2007-08-06 2008-08-04 Moduladores de gamma secretasa

Country Status (10)

Country Link
US (1) US20110009392A1 (es)
EP (1) EP2185522A1 (es)
JP (1) JP2010535762A (es)
AR (1) AR068052A1 (es)
CA (1) CA2695543A1 (es)
CL (1) CL2008002308A1 (es)
MX (1) MX2010001506A (es)
PE (1) PE20090957A1 (es)
TW (1) TW200911266A (es)
WO (1) WO2009020580A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
US7923563B2 (en) 2004-10-26 2011-04-12 Eisai R&D Management Co., Ltd. Amorphous object of cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
NZ568050A (en) 2005-11-24 2010-09-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
SA07280403B1 (ar) 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
CL2008000582A1 (es) 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AU2008292390B2 (en) 2007-08-31 2013-04-04 Eisai R & D Management Co., Ltd. Polycyclic compound
CA2742897A1 (en) 2008-11-06 2010-05-14 Astrazeneca Ab Modulators of amyloid beta.
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2013150349A (ru) 2011-04-13 2015-05-20 Мерк Шарп И Доум Корп. 5-замещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов васе, содержащие их композиции и их применение
MX2014002113A (es) 2011-08-22 2014-04-25 Merck Sharp & Dohme Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
CN105263922B (zh) 2013-06-04 2018-08-17 阿克图拉姆生命科学股份公司 三唑化合物及其作为γ分泌酶调节剂的用途
ES2665421T3 (es) 2013-06-04 2018-04-25 Acturum Real Estate Ab Compuestos de pirimidina y su uso como moduladores de la gamma secretasa
US11349879B1 (en) 2013-07-28 2022-05-31 Secureauth Corporation System and method for multi-transaction policy orchestration with first and second level derived policies for authentication and authorization
JP6628805B2 (ja) 2015-02-03 2020-01-15 ファイザー・インク 新規シクロプロパベンゾフラニルピリドピラジンジオン
CN105218457A (zh) * 2015-09-21 2016-01-06 山东大学 一种3,5,5’-三取代-2-乙内酰硫脲的制备方法
US10652248B2 (en) * 2016-07-28 2020-05-12 Molecula Corp. Systems and methods of managing data rights and selective data sharing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004247013B2 (en) * 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP2007538024A (ja) * 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
NZ568050A (en) * 2005-11-24 2010-09-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound

Also Published As

Publication number Publication date
TW200911266A (en) 2009-03-16
AR068052A1 (es) 2009-11-04
JP2010535762A (ja) 2010-11-25
WO2009020580A1 (en) 2009-02-12
CL2008002308A1 (es) 2009-07-17
MX2010001506A (es) 2010-03-10
EP2185522A1 (en) 2010-05-19
US20110009392A1 (en) 2011-01-13
CA2695543A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
PE20090957A1 (es) Moduladores de gamma secretasa
CY1124284T1 (el) Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20210396A1 (es) Moduladores de la via de estres integrada
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20190731A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20091095A1 (es) Moduladores de gamma secretasa
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20090363A1 (es) Moduladores de la gamma secretasa
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
PE20171342A1 (es) Compuestos y su uso como inhibidores de bace
PE20061295A1 (es) Derivados de acetileno
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20071090A1 (es) 5-pirazolpiperidinas-(sustituidas)
PE20120057A1 (es) Compuestos de tiazolopiridina moduladores de sirtuina
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp

Legal Events

Date Code Title Description
FC Refusal